StockData
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) stock

CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$0.86−0.02 (-2.28%)

Close on Nov 20, 2026Market cap $86.48MP/E –Yield –

Cardiol Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -C$34.32M. The highest annual figure on record is -C$20.69M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-C$34.32M–
FY2024Dec 31, 2024-C$40.28M–
FY2023Dec 31, 2023-C$29.79M–
FY2022Dec 31, 2022-C$41.34M–
FY2021Dec 31, 2021-C$38.66M–
FY2020Dec 31, 2020-C$20.69M–

More Cardiol Therapeutics figures

See a number that looks wrong?